Galapagos N.V. Q3 FY2024 earnings call

Paul Stoffels highlighted Galapagos as a pure-play biotech with a renewed R&D strategy, focused pipeline, and competitive technology platforms. Key progress includes IND clearance for GLPG5101, regulatory and operational progress with decentralized CAR-T network, and a robust pipeline with over 15 preclinical programs. Thad Huston discussed financial results, reaffirmed full year cash burn guidance of EUR370 million to EUR410 million for 2024, cash position of EUR3.3 billion at end of Q3, and collaborations with Blood Centers of America and Excellos for cell therapy manufacturing. Milestones included resumption of GLPG5301 study, enrollment in Phase II studies with GLPG3667, and plans to present new data at ASH.

No detailed product segment financial performance with revenue contribution % provided in the transcript.

Reconfirmed full year cash burn guidance for 2024 at EUR370 million to EUR410 million. Target to initiate at least four IND or CTA-enabling studies in 2025 across different modalities and indications. Aim to fuel clinical pipeline with at least two new clinical assets annually from 2026 onwards. Cash balance at end of Q3 was EUR3.3 billion, supporting pipeline build-out.

Forward-looking statements involve risks and uncertainties as actual results may differ materially from expressed or implied statements. No specific detailed operational failure risks discussed in depth.

Q: On the BCMA CAR-T 5301 in multiple myeloma, thoughts on Parkinsonism phase and future enrollment criteria?

A: Jeevan Shetty explained that BCMA-targeted CAR-Ts can lead to Parkinsonism, but steps taken include expansive discussion between medical monitor and investigator, and confidence in moving forward with the platform using seven day vein-to-vein fresh cells.

Q: Color on data to be presented at ASH for EUPLAGIA and ATALANTA?

A: Jeevan Shetty stated data is embargoed until November 5 at 9:00 a.m. per ASH embargo, and abstracts will be released then.

Q: Approach to BD next year?

A: Thad Huston said they continually look to broaden portfolio through BD, focused on oncology and immunology, including precision oncology and CAR-T.

Q: Scope for CAR-T programs like 5101 to enter market earlier than 2028?

A: Paul Stoffels said they'll follow scientific and regulatory process, evaluate data from Phase II expansion study to determine timelines.

Q: On 5101, test runs, vein-to-vein time, manufacturing barriers?

A: Jeevan Shetty said median seven day vein-to-vein time intact, productive interactions with FDA, consistent approach in U.S. and EU.

Q: New bispecific CAR-T strategy?

A: Paul Stoffels said team developed armed bispecific CAR-T with preclinical data, progressing to preclinical evaluation and clinic next year.

Q: CAR-T prioritization for autoimmune?

A: Paul Stoffels said still interested in autoimmune space but carefully choosing best-in-class products.

Q: TYK2 program timelines?

A: Wulf Bocher explained TYK2 inhibitor's mechanism, preserving IL-10 pathway, studies progressing with data expected in 2025-2026.

Q: Capital allocation for BD vs internal pipeline?

A: Thad Huston said focused on internal pipeline but also allocating to BD to broaden portfolio.

Q: Steps for activating other CAR-T manufacturing sites?

A: Thad Huston said tech transfer takes time, sites structured with CDMO services, working on Thermo Fisher and other sites.